Sight Sciences Stock Performance
| SGHT Stock | USD 4.21 0.05 1.20% |
Sight Sciences holds a performance score of 22 on a scale of zero to a hundred. The entity has a beta of 0.93, which indicates possible diversification benefits within a given portfolio. Sight Sciences returns are very sensitive to returns on the market. As the market goes up or down, Sight Sciences is expected to follow. Use Sight Sciences downside variance, and the relationship between the sortino ratio and accumulation distribution , to analyze future returns on Sight Sciences.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Sight Sciences are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain technical indicators, Sight Sciences unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Sight Sciences Q1 Earnings Taking a Look at Key Metrics Versus Estimates | 05/08/2025 |
2 | Acquisition by Burbach Gerhard F of 74766 shares of Sight Sciences subject to Rule 16b-3 | 05/12/2025 |
3 | Sight Sciences, Inc. Surges 44 percent Yet Its Low PS Is No Reason For Excitement | 05/14/2025 |
4 | Acquisition by Matthew Link of 6631 shares of Sight Sciences at 3.018 subject to Rule 16b-3 | 05/16/2025 |
5 | Disposition of 13066 shares by Alison Bauerlein of Sight Sciences at 3.477 subject to Rule 16b-3 | 05/19/2025 |
6 | Sight Sciences Receives Increased Price Target from Citigroup SGHT Stock News | 05/22/2025 |
7 | Acquisition by Encrantz Staffan of 41346 shares of Sight Sciences at 3.436 subject to Rule 16b-3 | 05/27/2025 |
8 | Acquisition by Encrantz Staffan of 26715 shares of Sight Sciences at 3.516 subject to Rule 16b-3 | 05/28/2025 |
9 | Acquisition by Encrantz Staffan of 60128 shares of Sight Sciences at 3.588 subject to Rule 16b-3 | 05/29/2025 |
10 | Acquisition by Encrantz Staffan of 42753 shares of Sight Sciences at 3.67 subject to Rule 16b-3 | 05/30/2025 |
11 | Acquisition by Encrantz Staffan of 30799 shares of Sight Sciences at 3.878 subject to Rule 16b-3 | 06/02/2025 |
12 | Acquisition by Encrantz Staffan of 25230 shares of Sight Sciences at 3.967 subject to Rule 16b-3 | 06/03/2025 |
13 | Acquisition by Encrantz Staffan of 21674 shares of Sight Sciences at 4.172 subject to Rule 16b-3 | 06/04/2025 |
14 | Acquisition by Encrantz Staffan of 27900 shares of Sight Sciences at 4.22 subject to Rule 16b-3 | 06/06/2025 |
15 | Disposition of 1810 shares by Jeremy Hayden of Sight Sciences at 3.259 subject to Rule 16b-3 | 06/16/2025 |
16 | Acquisition by Encrantz Staffan of 120000 shares of Sight Sciences at 2.53 subject to Rule 16b-3 | 06/24/2025 |
17 | Sight Sciences Raised to Hold at Wall Street Zen | 07/01/2025 |
| Begin Period Cash Flow | 138.1 M |
Sight Sciences Relative Risk vs. Return Landscape
If you would invest 221.00 in Sight Sciences on April 6, 2025 and sell it today you would earn a total of 200.00 from holding Sight Sciences or generate 90.5% return on investment over 90 days. Sight Sciences is currently generating 1.1232% in daily expected returns and assumes 4.0202% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Sight, and 78% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sight Sciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sight Sciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sight Sciences, and traders can use it to determine the average amount a Sight Sciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2794
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SGHT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.02 actual daily | 36 64% of assets are more volatile |
Expected Return
| 1.12 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.28 actual daily | 22 78% of assets perform better |
Based on monthly moving average Sight Sciences is performing at about 22% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sight Sciences by adding it to a well-diversified portfolio.
Sight Sciences Fundamentals Growth
Sight Stock prices reflect investors' perceptions of the future prospects and financial health of Sight Sciences, and Sight Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sight Stock performance.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.63) % | ||||
| Operating Margin | (0.79) % | ||||
| Current Valuation | 149.36 M | ||||
| Shares Outstanding | 51.7 M | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 2.79 X | ||||
| Revenue | 79.87 M | ||||
| Gross Profit | 66.91 M | ||||
| EBITDA | (45.9 M) | ||||
| Net Income | (51.51 M) | ||||
| Cash And Equivalents | 220.1 M | ||||
| Cash Per Share | 4.60 X | ||||
| Total Debt | 40.36 M | ||||
| Debt To Equity | 0.18 % | ||||
| Book Value Per Share | 1.51 X | ||||
| Cash Flow From Operations | (22.35 M) | ||||
| Earnings Per Share | (0.98) X | ||||
| Total Asset | 142.84 M | ||||
| Retained Earnings | (346.3 M) | ||||
About Sight Sciences Performance
Assessing Sight Sciences' fundamental ratios provides investors with valuable insights into Sight Sciences' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Sight Sciences is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company was incorporated in 2010 and is headquartered in Menlo Park, California. Sight Sciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 212 people.Things to note about Sight Sciences performance evaluation
Checking the ongoing alerts about Sight Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sight Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sight Sciences appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 79.87 M. Net Loss for the year was (51.51 M) with profit before overhead, payroll, taxes, and interest of 66.91 M. | |
| Sight Sciences currently holds about 220.1 M in cash with (22.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.6, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sight Sciences has a very weak financial position based on the latest SEC disclosures | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Sight Sciences Raised to Hold at Wall Street Zen |
- Analyzing Sight Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sight Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Sight Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sight Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sight Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sight Sciences' stock. These opinions can provide insight into Sight Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sight Stock Analysis
When running Sight Sciences' price analysis, check to measure Sight Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sight Sciences is operating at the current time. Most of Sight Sciences' value examination focuses on studying past and present price action to predict the probability of Sight Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sight Sciences' price. Additionally, you may evaluate how the addition of Sight Sciences to your portfolios can decrease your overall portfolio volatility.